- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00774527
Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT (CyFluCyATG)
Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a prospective, randomized, non-blind study.
Conditioning therapy will start on day -5 in patients who are randomized to receive Cy+ATG. Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter. Mesna 12 mg/kg iv push immediately before Cy and 3, 6, 9, and 12 hours after Cy. Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2. Premedication for ATG (ALG) will include methylprednisolone 2 mg/kg iv infusion, Tylenol 600 mg po, and Avil 45.5 mg iv push. The doses of cyclophosphamide and ATG (ALG) will be calculated using actual body weight.
Conditioning therapy will start on day -6 in patients who are randomized to receive Cy+fludarabine (Fludara®, Berlex Laboratories, Richmond, CA)+ATG. Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2). Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2. Premedication for ATG (ALG) will include methylprednisolone 2 mg/kg iv infusion, Tylenol 600 mg po, and Avil 45.5 mg iv push. Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -3. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -3 to -2 by pump through a central venous catheter. Mesna 12 mg/kg iv push immediately before Cy and 3, 6, 9, and 12 hours after Cy. The doses of cyclophosphamide and ATG (ALG) will be calculated using actual body weight.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Seoul, Korea, Republikken, 138-736
- Asan Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients with bone marrow failure syndrome.
- Written informed consent must be obtained from the patients and donors.
- Patients should have an HLA-identical or one-locus mismatched sibling, family or unrelated donor who is 60 years or less.
- Patients should be 15 years of age or older, but younger than 60 years.
- The performance status of the patients should be 70 or over by Karnofsky performance scale (see Appendix I).
- Patients should not have major illness or organ failure.
- Patients must have adequate hepatic function (bilirubin less than 2 mg/dl, AST and ALT less than three times the upper normal limit).
- Patients must have adequate renal function (creatinine less than 2.0 mg/dl).
- Patients must have adequate cardiac function (ejection fraction > 45% on MUGA scan).
- Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlikely, and making informed consent impossible.
- Patients must not be in pregnancy.
Exclusion Criteria:
- Patients should have major illness or organ failure
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Ingen inngripen: ArmI(CyATG)
•Conditioning therapy will start on day -5 in patients who are randomized to receive Cy+ATG.
Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5.
Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter
|
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Occurrence of regimen related toxicities
Tidsramme: 7 years
|
1.1 Compare the regimen related toxicities of two different conditioning regimens, cyclophosphamide (Cy)+anti-thymocyte globulin (ATG) (Cy-ATG) vs. reduced dose of Cy+fludarabine (Flu)+ATG (Cy-Flu-ATG) after allogeneic hematopoietic cell transplantation (allo-HCT).
|
7 years
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Secondary end point will be the occurrence of engraftment failure (primary and secondary)
Tidsramme: 7years
|
7years
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Kyoo-Hyung Lee, Doctor, Asan Medical Center
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Sykdom
- Benmargssykdommer
- Hematologiske sykdommer
- Anemi
- Anemi, hemolytisk
- Myelodysplastiske syndromer
- Syndrom
- Anemi, aplastisk
- Benmargssviktforstyrrelser
- Pancytopeni
- Hemoglobinuri, Paroksysmal
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Antirevmatiske midler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Cyklofosfamid
- Fludarabin
- Antilymfocyttserum
Andre studie-ID-numre
- C-002
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Benmargssviktsyndrom
-
University Hospital FreiburgFullførtMyelodysplastiske syndromer | Fanconi anemi | Dyseratosis Congenita | Pearson Marrow-pancreas syndrom | Shwachman-diamant syndromSpania, Tyskland, Sveits, Østerrike, Nederland, Italia, Tsjekkisk Republikk, Belgia, Danmark, Irland
Kliniske studier på Cyclophosphamide-fludarabine-anti thymocyte globulin
-
The Christie NHS Foundation TrustAvsluttetCD19 Positivt Non-Hodgkin lymfomStorbritannia
-
Ohio State University Comprehensive Cancer CenterCelgene CorporationRekrutteringKutant T-celle lymfom | Perifert T-celle lymfom | T-prolymfocytisk leukemi | T-Large Granulocytic Leukemi | T-lymfoblastisk leukemi/lymfomForente stater
-
Assistance Publique - Hôpitaux de ParisUkjent
-
Wright State UniversitySanofi; University of Nebraska; University of Arizona; The Methodist Hospital... og andre samarbeidspartnereFullførtSluttstadium nyresykdom | NyresviktForente stater
-
Emory UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes...FullførtSigdcellesykdomForente stater
-
M.D. Anderson Cancer CenterFullførtKronisk lymfatisk leukemi | Myelodysplastisk syndrom | Akutt myelogen leukemiForente stater
-
M.D. Anderson Cancer CenterFullførtAplastisk anemiForente stater
-
Michael Pulsipher, MDAktiv, ikke rekrutterendeAlvorlig aplastisk anemiForente stater
-
M.D. Anderson Cancer CenterFullførtMyelofibroseForente stater
-
Medical University of South CarolinaCSL BehringFullførtCytomegalovirus sykdomForente stater